Daihan Pharmaceutical Co.Ltd Cash Flow Conversion Efficiency
Daihan Pharmaceutical Co.Ltd cash flow conversion efficiency. Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.47 Billion ≈ $6.42 Million USD) by net assets (₩293.27 Billion ≈ $198.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Daihan Pharmaceutical Co.Ltd for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Daihan Pharmaceutical Co.Ltd (2014–2024)
Cash flow conversion efficiency of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart illustrates how Daihan Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Daihan Pharmaceutical Co.Ltd stock quote for real-time trading data and today's change.
Daihan Pharmaceutical Co.Ltd Cash Flow Conversion Ratio Explained
Daihan Pharmaceutical Co.Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Daihan Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency. Review Daihan Pharmaceutical Co.Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ReaLy Development & Construction
TWO:2596
|
0.055x |
|
CLERHP Estructuras S.A
MC:CLR
|
-0.061x |
|
Scope Fluidics SA
WAR:SCP
|
-0.102x |
|
NextEye Co. Ltd
KQ:137940
|
-0.144x |
|
MEI Pharma Inc
NASDAQ:MEIP
|
-0.145x |
|
Chaintech Technology Corp
TW:2425
|
-0.029x |
|
Kluang Rubber Company Malaya
KLSE:2453
|
0.001x |
|
GKW Limited
NSE:GKWLIMITED
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. Also see balance sheet size of Daihan Pharmaceutical Co.Ltd for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩275.99 Billion ≈ $187.04 Million |
₩35.64 Billion ≈ $24.15 Million |
0.129x | -17.59% |
| 2023-12-31 | ₩247.97 Billion ≈ $168.05 Million |
₩38.86 Billion ≈ $26.34 Million |
0.157x | +21.80% |
| 2022-12-31 | ₩225.40 Billion ≈ $152.75 Million |
₩29.00 Billion ≈ $19.65 Million |
0.129x | -35.76% |
| 2021-12-31 | ₩202.81 Billion ≈ $137.44 Million |
₩40.62 Billion ≈ $27.53 Million |
0.200x | +8.35% |
| 2020-12-31 | ₩181.92 Billion ≈ $123.29 Million |
₩33.63 Billion ≈ $22.79 Million |
0.185x | -12.58% |
| 2019-12-31 | ₩166.78 Billion ≈ $113.02 Million |
₩35.26 Billion ≈ $23.90 Million |
0.211x | -33.96% |
| 2018-12-31 | ₩140.36 Billion ≈ $95.12 Million |
₩44.94 Billion ≈ $30.46 Million |
0.320x | +81.40% |
| 2017-12-31 | ₩115.88 Billion ≈ $78.53 Million |
₩20.45 Billion ≈ $13.86 Million |
0.177x | -41.25% |
| 2016-12-31 | ₩92.94 Billion ≈ $62.99 Million |
₩27.92 Billion ≈ $18.92 Million |
0.300x | +28.43% |
| 2015-12-31 | ₩76.84 Billion ≈ $52.07 Million |
₩17.98 Billion ≈ $12.18 Million |
0.234x | +58.11% |
| 2014-12-31 | ₩64.10 Billion ≈ $43.44 Million |
₩9.48 Billion ≈ $6.43 Million |
0.148x | -- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.